New Drug Combination Shows Promise for T-Cell Lymphoma Treatment
A groundbreaking study reveals that the combination of duvelisib and romidepsin offers a safe and effective treatment for relapsed T-cell lymphomas, improving patient outcomes and eligibility for stem cell transplants.
Relapsed or refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive forms of blood cancers that often do not respond to standard treatments. Patients with these lymphomas typically require stem cell transplants to potentially cure the disease; however, controlling the disease beforehand is crucial for successful transplantation.
A recent study led by researchers from the PETAL Consortium at Mass General Brigham investigated a novel drug combination involving duvelisib and romidepsin. The findings demonstrated that this combination is effective, well-tolerated, and safe for patients battling R/R PTCL and CTCL. The significance of this study lies in its potential to help patients achieve disease control, making them eligible for stem cell transplantation.
The research, published in lood Advances025, involved treating 38 patients with the drug duo, monitoring outcomes such as tumor reduction, survival rates, and side effects. Results showed that 61% of patients experienced a reduction or elimination of cancer, with nearly half (47%) having no detectable disease. Importantly, 11 patients subsequently underwent stem cell transplants.
Notably, among patients with the nodal T-follicular helper cell lymphoma subtype, an impressive 82% responded positively to the treatment. The side effects were manageable, though there was one fatality related to treatment complications.
Dr. Salvia Jain, a senior author, emphasized that the study’s outcomes support the use of duvelisib and romidepsin as a safe and effective option. The researchers hope this will lead to better access through insurance coverage and regulatory approval. Future research aims to identify markers that predict response or resistance to personalize treatment and improve outcomes.
This breakthrough offers new hope for patients with difficult-to-treat T-cell lymphomas, paving the way for improved therapeutic strategies and increased chances for successful stem cell transplants.
Source: https://medicalxpress.com/news/2025-07-drug-combination-effective-cell-lymphoma.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Investigating the Causes of Lung Damage in Autoimmune Diseases
New research uncovers the role of immune cell exhaustion in lung damage caused by autoimmune diseases like systemic sclerosis and Sjögren's syndrome, offering potential for targeted therapies.
Artificial Intelligence Develops Two Novel Antibiotics Against Drug-Resistant Superbugs
MIT researchers have used AI to design two new antibiotics targeting resistant superbugs, marking a promising advancement in overcoming antimicrobial resistance. While further testing is needed, this innovative approach could transform future infectious disease treatments.
Innovative Herpes Virus-Based Vaccine Shows Potential in Cancer Treatment Without Side Effects
A novel herpes virus-based cancer vaccine shows promise in targeting tumors effectively without causing side effects, offering new hope for cancer therapies.